Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Provided By GlobeNewswire
Last update: Jul 14, 2025
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025
Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase
Read more at globenewswire.comNASDAQ:FBIO (11/21/2025, 4:30:02 PM)
2.59
+0.06 (+2.37%)
7.46
-0.08 (-1.06%)
Find more stocks in the Stock Screener
